Focus Partners Wealth Acquires 105,220 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Focus Partners Wealth raised its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 721.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 119,804 shares of the company’s stock after purchasing an additional 105,220 shares during the period. Focus Partners Wealth’s holdings in Elanco Animal Health were worth $1,451,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. CoreCap Advisors LLC bought a new stake in Elanco Animal Health in the fourth quarter valued at approximately $29,000. Jones Financial Companies Lllp increased its stake in Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after purchasing an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. increased its stake in Elanco Animal Health by 221.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock valued at $60,000 after purchasing an additional 3,411 shares in the last quarter. MRP Capital Investments LLC bought a new stake in Elanco Animal Health in the fourth quarter valued at approximately $61,000. Finally, Blue Trust Inc. increased its stake in Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after purchasing an additional 1,894 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on ELAN shares. Piper Sandler lowered their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, March 6th. Stifel Nicolaus upped their price target on shares of Elanco Animal Health from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Barclays reduced their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. UBS Group reduced their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Finally, Morgan Stanley reduced their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Elanco Animal Health has a consensus rating of “Hold” and an average price target of $15.00.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $12.94 on Friday. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.80. The firm has a fifty day simple moving average of $10.11 and a 200 day simple moving average of $11.44. The stock has a market capitalization of $6.42 billion, a price-to-earnings ratio of 32.34, a PEG ratio of 2.50 and a beta of 1.49. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the prior year, the company posted $0.34 earnings per share. The firm’s revenue was down 1.0% on a year-over-year basis. Research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, March 11th. The stock was acquired at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the acquisition, the director now owns 111,459 shares of the company’s stock, valued at $1,136,881.80. This trade represents a 9.86% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.89% of the stock is currently owned by corporate insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.